5734-67-8

Basic information

• Product Name: 4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE
• Synonyms: 4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE;2-AMINO-4-CHLORO-6-ETHYLPYRIMIDINE ;4-Chloro-6-ethyl-pyrimidin-2-ylamine;2-Pyrimidinamine, 4-chloro-6-ethyl-;4-chloro-2-diazenyl-6-ethylpyrimidine;4-Chloro-6-ethylpyrimidin-2-amine, 2-Amino-4-chloro-6-ethyl-1,3-diazine
• CAS NO: 5734-67-8
• Molecular Formula: C₆H₈ClN₃
• Molecular Weight: 157.60082
• Product Categories: Drug Intermediates
• Mol File: 5734-67-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 319.988 °C at 760 mmHg
• Flash Point: 147.324 °C
• Appearance: /
• Density: 1.282 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.584
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE(5734-67-8)
• EPA Substance Registry System: 4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE(5734-67-8)

Safety Data

• Hazardous Substances Data: 5734-67-8(Hazardous Substances Data)

Usage

General Description

4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE is a chemical compound with the molecular formula C6H8ClN3. It is a pyrimidine derivative with a chloro and ethyl substituent on the 4th and 6th carbon atoms, respectively. 4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has been studied for its potential antitumor and antiviral properties, and has also been investigated as a potential herbicide. Due to its diverse range of applications, 4-CHLORO-6-ETHYL-2-PYRIMIDINAMINE has garnered significant interest in the fields of medicinal chemistry and agricultural science.

InChI:InChI=1/C6H8ClN3/c1-2-4-3-5(7)10-6(8)9-4/h3H,2H2,1H3,(H2,8,9,10)

Upstream product

• 5734-66-7 6-ethylisocytosine 
• 30414-53-0 methyl propanoyl acetate 
• 5734-66-7 2-amino-6-ethylpyrimidin-4-ol 

Downstream Products

• 570415-02-0 6-ethyl-N₄-[3-fluoro-4-(4-pyridinylsulfanyl)phenyl]-2,4-pyrimidinediamine 
• 569658-12-4 4-({4-[(2-amino-6-ethyl-4-pyrimidinyl)amino]phenyl}sulfanyl)phenol 
• 570415-41-7 N-(2-amino-6-ethyl-4-pyrimidinyl)-N-[4-(4-pyridinylsulfanyl)phenyl]amine 
• 514854-13-8 2,4-diamino-6-ethyl-5-iodopyrimidine 
• 58-14-0 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine 
• 514854-12-7 2,4-diamino-6-ethylpyrimidine 
• 514854-15-0 2-amino-6-ethyl-4-methoxypyrimidine 
• 1193-85-7 4-ethylpyrimidin-2-amine 

Relevant articles and documents

4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity

Despite the high diversity of histamine H3 receptor (H3R) antagonist/inverse agonist structures, partial or full H3R agonists have typically been imidazole derivatives. An in-house screening campaign intriguingly afforded

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Structural studies on bioactive compounds. Part 37. Suzuki coupling of diaminopyrimidines: A new synthesis of the antimalarial drug pyrimethamine

Suzuki reactions have been used successfully to effect cross-coupling of 5-halopyrimidines with 4-chlorobenzeneboronic acid and 2,4-diamino-5-(4-chloro-3-halo)-6-ethylpyrimidines with 4-methoxybenzeneboronic acid. The antimalarial drug pyrimethamine has been prepared by coupling 2,4-diamino-6-ethyl-5-iodopyrimidine with 4-chlorobenzeneboronic acid.